The United States Patent and Trademark Office (USPTO) has introduced a pilot program to provide prioritized patent examination for patent applications that cover a product or process related to COVID-19. The product or process must be subject to an applicable U.S. Food and Drug Administration (FDA) approval for COVID-19 use.Continue reading
Tucson, Ariz. – The University of Arizona and state of Arizona antibody testing initiative will include 31 sites across the state as it expands to all 15 counties.Continue reading
Sarah Arrowsmith, lab coordinator and scientist at Biodesign Institute Center for Environmental Biotechnology, stepped up to make coth masks for others. The team at the ASU Biodesign institute ran tests to determine how effective these homemade masks may be. Continue reading
After a comprehensive search, the Biotechnology Innovation Organization (BIO) has announced that Michelle McMurry-Heath, MD, PhD, as its incoming President and CEO. McMurry-Heath will become the organization’s next President and CEO on June 1, 2020.
BIO is the world’s largest science and public advocacy organization, representing 1,000 members. McMurry-Heath will succeed former Rep. Jim Greenwood, who has led the organization since 2005 and BIO’s founding President & CEO Carl B. Feldbaum who served from 1993 to 2004.Continue reading
- Testing – What is the difference between tests?
- Testing – Who needs it and when?
- Testing – How can we get the job done?
TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nasdaq: PRVB) are proud to announce their collaboration to significantly improve the scientific community’s insight into type 1 diabetes (T1D) through Provention’s contribution of data from the Phase III Protégé study of teplizumab to the T1D Trial Outcome Measures Initiative (TOMI) integrated database. The Protégé study evaluated teplizumab on the preservation of beta cell function in newly onset T1D patients and generated the largest disease modifying interventional clinical trial dataset in T1D with more than 500 patients.Continue reading
“This is not a green light to speed, this is a green light to proceed, and we are going to proceed with caution,” Arizona Governor Doug DuceyContinue reading
Washington, DC (May 12, 2020) – The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by biopharmaceutical innovators to combat – and ultimately eradicate – the novel coronavirus. Continue reading
- Unprecedented program convenes manufacturers and pharmacies to help millions of Americans access prescription medications at affordable and predictable prices
- Express Scripts Parachute RxSM will cap costs at $25 for a 30-day supply of generic drugs; $75 for a 30-day supply of brand-name medicines for a limited time
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced availability of a newly created “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”
“This guidance seeks to help AdvaMed members and other medical technology companies develop and implement processes that both support rapid decision-making in the context of the pandemic and mitigate any related compliance risks,” said Christopher L. White, AdvaMed COVID action team leader, chief operating officer and general counsel.Continue reading